

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 3 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

**Amendments to the Claims:**

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)
2. (Withdrawn) A method for elevating the plasma level of HDL cholesterol in a human subject in need thereof comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about 800 mg per day.
3. (Withdrawn) The method of claim 2 wherein the plasma level of HDL cholesterol is elevated by at least 5% as compared to the level prior to treatment and/or above at least 30 mg/DL.
4. (Withdrawn) The method of claim 3 further comprising maintaining the plasma level of HDL cholesterol at least 5% above the level prior to the treatment and/or above at least 30 mg/DL.
5. (Withdrawn) A method for decreasing the plasma level of LDL cholesterol in a human subject in need thereof comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about 800 mg per day.
6. (Withdrawn) The method of claim 5 wherein the plasma level of LDL cholesterol is decreased by at least 10% as compared to the level prior to treatment and/or below at least 190 mg/DL.

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 4 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

7. (Withdrawn) The method of claim 6 further comprising maintaining the plasma level of LDL cholesterol at least 10% below the level prior to treatment and/or below at least 190 mg/DL.

8. (Withdrawn) A method for decreasing the plasma level of triglycerides in a human subject in need thereof comprising periodically orally administering to a human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about 800 mg per day.

9. (Withdrawn) The method of claim 8 wherein the plasma level of triglycerides is decreased by at least 10% as compared to the level prior to treatment and/or below at least 200 mg/DL.

10. (Withdrawn) The method of claim 9 further comprising maintaining the plasma level of triglycerides at least 10% below the level prior to treatment and/or below at least 200 mg/DL.

11. (Currently amended) A method for the treatment of ~~dislipoproteinemia~~ dyslipoproteinemia in a human subject in need thereof comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about ~~800~~ 400 mg per day.

12. (Withdrawn) A method for the treatment of hyperlipidemia in a human subject in need thereof comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about 800 mg per day.

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 5 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

13. (Withdrawn) A method for the treatment of hypertension in a human subject in need thereof comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30mg per day to about 800 mg per day.

14. (Withdrawn) The method of claim 13 wherein the cystolic and/or diastolic blood pressure is decreased to below at least 160mmHg systolic and/or 100mmHg diastolic.

15. (Withdrawn) The method of claim 14 further comprising maintaining the blood pressure below at least 160mmHg systolic and/or 100mmHg diastolic.

16. (Withdrawn) A method of delaying the onset of non-insulin dependent diabetes mellitus in a human subject susceptible thereto comprising periodically orally administering to the human subject 3,3,14,14-tetramethylhexadecane-1,16-dioic acid in a range from about 30 mg per day to about 800 mg per day.

17. (Withdrawn) The method of claim 16 whereby the insulin resistance is decreased.

18. (Withdrawn) The method of claim 16 whereby the plasma level of fasting glucose is decreased to below at least 126 mg/DL.

19. (Withdrawn) The method of claim 18 further comprising maintaining the plasma level below at least 126 mg/DL.

20-21. (Canceled)

Applicants : Jacob Bar-Tana and Ihor Bekersky  
Serial No. : 10/585,017  
Filed : June 28, 2008  
Page 6 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

22. (Currently amended) The method of claim ~~[[1]]~~ 11, wherein the amount is from about 100 mg per day to about ~~600~~ 400 mg per day.

23. (Currently Amended) The method of claim ~~[[1]]~~ 11, wherein the amount is from about 200 mg per day to about 400 mg per day.

24. (Currently amended) The method of claim ~~[[1]]~~ 11, wherein the human subject is a female and the amount is from about 30 mg per day to about ~~600~~ 400 mg per day.

25. (Currently Amended) The method of claim ~~[[1]]~~ 11, wherein the periodic administration is effected twice daily.

26. (Currently Amended) The method of claim ~~[[1]]~~ 11, wherein the periodic administration is effected three times daily.

27. (Currently amended) The ~~methods~~ method of claim ~~[[1]]~~ 11, wherein the periodic administration is effected at least once daily for at least 14 days.

28. (Currently amended) The ~~methods~~ method of claim ~~[[1]]~~ 11, wherein the periodic administration is effected at least once daily for at least 21 days.

29. (Currently amended) The ~~methods~~ method of claim ~~[[1]]~~ 11, wherein the periodic administration is effected at least once daily for at least 30 days.

30. (New) The method of claim 11, wherein the amount is from about 100 mg per day to about 200 mg per day.

Applicants : Jacob Bar-Tana and Ihor Bekersky

Serial No. : 10/585,017

Filed : June 28, 2008

Page 7 of 14: Amendment in Response to July 6, 2010 Office  
Action, Supplemental Information Disclosure  
Statement and Petition for a Three-Month  
Extension of Time

31. (New) The method of claim 11, wherein the amount is about  
200 mg per day.